An observational study in Unresectable Stage III NSCLC, sponsored by Zhejiang Cancer Hospital. Status unknown. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-11-13.
Sponsored by Zhejiang Cancer Hospital · Observational
The chemoradiotherapy (CCRT) is still a standard treatment for the unresectabl stage III NSCLC.However, prognosis following this treatment is generally poor, with 5-year survival of 15-20%. The result of published HELPER study had showed that Endostar, a kind of angiogenesis agent, in combination with CCRT could improve the efficacy and safety. In order to verify the rusults, the investigators design the current study.
The current study is a observation study in the real world setting. The 500 patients in compliance with Enrollment Criteria will be as the objects of observation. The procedure of study include the period of screening, treating and follow-up. The duration of study is about two and half year. The data entrying will be done by CRC, using the EDC system. CRA will audit the quality of data regularly.
Zhejiang Cancer Hospital is the lead sponsor of 271 studies on the registry; 116 are open to participants now.
Counted across the registry records on this site, refreshed daily.
the patients with untreated pathologically confirmed inoperable stage III NSCLC, suitable for the treatment of CCRT
Exclusion Criteria:
history of other malignant diseases, uncontrolled hypertension, any contraindications to chemoradiotherapy, pregnancy, breastfeeding or preexisting bleeding diatheses.
-
PFS
progress free survival
Time frame: 15 months
OS
Overall survival
Time frame: 3 years
LRFS
Locoregional relapse-free survival
Time frame: 2 years
DMFS
Distant metastasis-free survival
Time frame: 2 years
AEs
adverse events
Time frame: 3 years
No study locations are listed for this record.
Plan to share: No — Only principlal investigator has the right to use all the data collected. The individual participant will not be allowed to share the data among them.
No publications or documents are linked to this record.
This study is status unknown, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhejiang Cancer Hospital